Anti-Inflammatory Therapy to Augment CF transmembrane conductance regulator (CFTR) Rescue in Cystic Fibrosis (CF) Patients.

Trial Profile

Anti-Inflammatory Therapy to Augment CF transmembrane conductance regulator (CFTR) Rescue in Cystic Fibrosis (CF) Patients.

Not yet recruiting
Phase of Trial: Phase 0

Latest Information Update: 02 Aug 2018

At a glance

  • Drugs Losartan (Primary)
  • Indications Cystic fibrosis
  • Focus Proof of concept; Therapeutic Use
  • Most Recent Events

    • 26 Jul 2018 Planned initiation date changed from 10 Jul 2018 to 10 Sep 2018.
    • 03 Apr 2018 Planned initiation date changed from 10 Mar 2018 to 10 Jul 2018.
    • 22 Feb 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top